News

ALXN

Alexion to Acquire Wilson Therapeutics for $855 Million

Edward Kim | Equities.com |

Wilson's lead product candidate is in Phase 3 trials to treat Wilson disease, a rare genetic liver disorder.


Alexion Announces Positive Phase 3 Results for Rare Blood Disorder Treatment

Edward Kim | Equities.com |

Study comparing investigational long-acting treatment vs Soliris, Alexion's approved drug.


​How Alexion Strengthens in Risk-Reward Equation

MoneyShow | Equities.com |

Alexion Pharmaceuticals researches and manufactures treatments of severe and rare health disorders.


What the Recent Run-Up in Ebola Stocks Taught Investors

The Life Sciences Report | Equities.com |

A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit


Biotech Stocks With Considerable Upside Potential

The Life Sciences Report | Equities.com |

Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where


Investing in the Best Canadian Biotech Stocks

The Life Sciences Report | Equities.com |

You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling


Biotech Investors Need to Focus on Catalysts

The Life Sciences Report | Equities.com |

When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The


J.P.Morgan's Geoff Meacham Plucks Biotechs with Upside from a Down Market

The Life Sciences Report | Equities.com |

A downtrending market is troublesome for investors, but does present interesting opportunities through creation of lower valuations. Finding the right names in the wobbly life sciences environment


Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust

The Life Sciences Report | Equities.com |

2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative


Stocks Make Late Mini-Rally as Wall Street is Up for the Third Straight Week

Michael Teague | Equities.com |

The Treasury Department on Friday reported a surplus of $113 billion for the month of April, with government revenue benefiting from the modest but consistent improvements in the economy. Combined


Sponsored Financial Content

Market Movers